These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study. Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583 [TBL] [Abstract][Full Text] [Related]
4. [Zoledronic acid (zoledronate) in children with osteogenesis imperfecta]. Sánchez-Sánchez LM; Cabrera-Pedroza AU; Palacios-Saucedo G; de la Fuente-Cortez B Gac Med Mex; 2015; 151(2):164-8. PubMed ID: 25946526 [TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid treatment in children with osteogenesis imperfecta. Vuorimies I; Toiviainen-Salo S; Hero M; Mäkitie O Horm Res Paediatr; 2011; 75(5):346-53. PubMed ID: 21293106 [TBL] [Abstract][Full Text] [Related]
6. Hypocalcemia associated with zoledronic acid for osteogenesis imperfecta. Das RR Horm Res Paediatr; 2011; 76(4):291; author reply 292. PubMed ID: 21912084 [No Abstract] [Full Text] [Related]
7. Novel mutations in FKBP10 in Chinese patients with osteogenesis imperfecta and their treatment with zoledronic acid. Xu XJ; Lv F; Liu Y; Wang JY; Ma DD; Asan ; Wang JW; Song LJ; Jiang Y; Wang O; Xia WB; Xing XP; Li M J Hum Genet; 2017 Feb; 62(2):205-211. PubMed ID: 27762305 [TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate treatment of children and adults with osteogenesis imperfecta: unanswered questions. Brizola E; Shapiro JR Calcif Tissue Int; 2015 Aug; 97(2):101-3. PubMed ID: 26071113 [TBL] [Abstract][Full Text] [Related]
9. [Effects of zoledronic acid in adults with osteogenesis imperfecta]. Pavón de Paz I; Iglesias Bolaños P; Durán Martínez M; Olivar Roldán J; Guijarro De Armas G; Parra García JI Endocrinol Nutr; 2010; 57(6):245-50. PubMed ID: 20510658 [TBL] [Abstract][Full Text] [Related]
10. Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta. Aström E; Magnusson P; Eksborg S; Söderhäll S Acta Paediatr; 2010 Dec; 99(12):1834-40. PubMed ID: 20726960 [TBL] [Abstract][Full Text] [Related]
11. Hearing in bisphosphonate-treated children with osteogenesis imperfecta: our experience in thirty six young patients. Ting TH; Zacharin MR Clin Otolaryngol; 2012 Jun; 37(3):229-33. PubMed ID: 22708940 [No Abstract] [Full Text] [Related]
12. [Biphosphonates and osteogenesis imperfecta in children]. Gandon-Laloum S Arch Pediatr; 2009 Jul; 16(7):1085-9. PubMed ID: 19423303 [TBL] [Abstract][Full Text] [Related]
13. Response to zolendronic acid in children with type III osteogenesis imperfecta. Panigrahi I; Das RR; Sharda S; Marwaha RK; Khandelwal N J Bone Miner Metab; 2010 Jul; 28(4):451-5. PubMed ID: 20131072 [TBL] [Abstract][Full Text] [Related]
14. [Influence of bisphosphonate treatment on the radiological features of osteogenesis imperfecta in children]. Chigladze TT; Zhvaniia MA; Bekua MV Georgian Med News; 2006 Feb; (131):62-5. PubMed ID: 16575136 [TBL] [Abstract][Full Text] [Related]
15. Zoledronate for Osteogenesis imperfecta: evaluation of safety profile in children. Kumar C; Panigrahi I; Somasekhara Aradhya A; Meena BL; Khandelwal N J Pediatr Endocrinol Metab; 2016 Aug; 29(8):947-52. PubMed ID: 27235668 [TBL] [Abstract][Full Text] [Related]
16. Pulmonary function tests in an infant with osteogenesis imperfecta and early biphosphonate treatment. Rugolotto S; Monti E; Carli M; Pietrobelli A; Antoniazzi F; Tato L Acta Paediatr; 2007 Dec; 96(12):1856-7. PubMed ID: 18001342 [No Abstract] [Full Text] [Related]
17. Decrease of serum alkaline phosphatase after three cycles of pamidronate disodium in children with severe osteogenesis imperfecta. Cabral de Menezes Filho H; Rodrigues JM; Radonsky V; Della Manna T; Kuperman H; Steinmetz L; Dichtchekenian V; Damiani D; Setian N Horm Res; 2007; 68 Suppl 5():207-8. PubMed ID: 18174750 [No Abstract] [Full Text] [Related]
19. Pain and quality of life of children and adolescents with osteogenesis imperfecta over a bisphosphonate treatment cycle. Tsimicalis A; Boitor M; Ferland CE; Rauch F; Le May S; Carrier JI; Ngheim T; Bilodeau C Eur J Pediatr; 2018 Jun; 177(6):891-902. PubMed ID: 29637375 [TBL] [Abstract][Full Text] [Related]